Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8BrF17 |
Molecular Weight | 498.962 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br
InChI
InChIKey=WTWWXOGTJWMJHI-UHFFFAOYSA-N
InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
DescriptionCurator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191624/
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191624/
Perflubron is a contrast agent used for signal enhancement during the indicated ultrasound imaging procedures. Perflubron is a constituent of blood substitute, indicated for liquid breathing.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.16 mg/dL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11171732 |
14 mL/kg single, respiratory dose: 14 mL/kg route of administration: Respiratory experiment type: SINGLE co-administered: |
PERFLUBRON serum | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Long-term tidal liquid ventilation in premature lambs: physiologic, biochemical and histological correlates. | 2003 |
|
Positive end-expiratory pressure modulates perfluorochemical evaporation from the lungs. | 2003 |
|
End-expiratory lung volumes and density distribution patterns during partial liquid ventilation in healthy and oleic acid-injured sheep: a computed tomography study. | 2003 Aug |
|
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma. | 2003 Aug 18 |
|
Mechanism of perfluoroalkyl halide toxicity: catalysis of perfluoroalkylation by reduced forms of cobalamin (vitamin B12). | 2003 Dec |
|
Transient increase in lung epithelial tight junction permeability: an additional mechanism for enhancement of lung transgene expression by perfluorochemical liquids. | 2003 Dec |
|
Dose-response effect of perfluorocarbon administration on lung microvascular permeability in rats. | 2003 Dec 1 |
|
Effect of partial liquid ventilation on bacterial clearance during Pseudomonas aeruginosa-induced lung injury in rats. | 2003 Jul |
|
Partial liquid ventilation does not affect BALF TNF-, MIP-2, CINC-1 concentrations, or CD11b cell surface expression, but does increase macrophage proportion among BALF cells in the acute phase of rat LPS-induced lung injury. | 2003 Jun |
|
Engineering blood: synthetic substitutes from fluorinated compounds. | 2003 Jun |
|
Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation. | 2003 Jun |
|
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. | 2003 Jun 16 |
|
The dependency of expiratory airway collapse on pump system and flow rate in liquid ventilated rabbits. | 2003 May 30 |
|
Perflubron emulsion improves hepatic microvascular integrity and mitochondrial redox state after hemorrhagic shock. | 2003 Nov |
|
Alternatives to blood in the 21st century. | 2004 |
|
Treatment of decompression sickness in swine with intravenous perfluorocarbon emulsion. | 2004 Apr |
|
Lung growth induced by prenatal instillation of perfluorocarbon into the fetal rabbit lung. | 2004 Apr |
|
Blood management in intensive care medicine: CRIT and ABC--what can we learn? | 2004 Apr |
|
Dose response to aerosolized perflubron in a neonatal swine model of lung injury. | 2004 Aug |
|
[Effects of perfluorochemicals on severe hemo-diluted cardiopulmonary bypass in dogs]. | 2004 Jan |
|
Assessment of the development of choked flow during total liquid ventilation. | 2004 Jan |
|
Effects of partial liquid ventilation on lipopolysaccharide-induced inflammatory responses in rats. | 2004 Jul |
|
Surface properties and the meconium aspiration syndrome. | 2004 Mar |
|
Effect of meconium on the surface properties of perflubron. | 2004 Mar |
|
Feasibility of lung cancer hyperthermia using breathable perfluorochemical (PFC) liquids. Part I: Convective hyperthermia. | 2004 May |
|
Comparison of aerosol therapy with different perfluorocarbons in surfactant-depleted animals. | 2004 May |
|
Perfluorocarbon emulsion improves cerebral oxygenation and mitochondrial function after fluid percussion brain injury in rats. | 2004 May |
|
Cosurfactant effect of a semifluorinated alkane at a fluorocarbon/water interface: impact on the stabilization of fluorocarbon-in-water emulsions. | 2004 May 11 |
|
[The impact of mechanical ventilation strategies that minimize atelectrauma in an experimental model of acute lung injury]. | 2004 May-Jun |
|
Molecular dynamics averaging of Xe chemical shifts in liquids. | 2004 Nov 15 |
|
Catheter tracking and visualization using 19F nuclear magnetic resonance. | 2004 Sep |
|
Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. | 2004 Sep |
|
Artificial O2 carriers: status in 2005. | 2005 |
|
Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. | 2005 |
|
Experimental studies on artificial blood usage for hemodilution during cardiopulmonary bypass. | 2005 Aug |
|
Postnatal lung mechanics, lung composition, and surfactant synthesis after tracheal occlusion vs prenatal intrapulmonary instillation of perfluorocarbon in fetal rabbits. | 2005 Jan |
|
Comparison of different inhalational perfluorocarbons in a rabbit model of acute lung injury. | 2005 Jan-Feb |
|
Intrapulmonary perfluorooctyl bromide instillation in fetal rabbits. | 2005 Jul |
|
Cardioprotective effect of perfluorochemical emulsion for cardiac preservation after six-hour cold storage. | 2005 Jul-Aug |
|
Hyperoxia-induced changes in human airway epithelial cells: the protective effect of perflubron. | 2005 Mar |
|
Inhibition of breathing after surfactant depletion is achieved at a higher arterial PCO2 during ventilation with liquid than with gas. | 2005 Mar 4 |
|
Brain pharmacokinetics of lignocaine before and following intravenous perfluorocarbon emulsion infusion in sheep. | 2005 May-Jun |
|
Effect of low-bias flow oscillation with partial liquid ventilation on fluoroscopic image analysis, gas exchange, and lung injury. | 2005 Nov |
|
Expiratory flow limitation during gravitational drainage of perfluorocarbons from liquid-filled lungs. | 2005 Nov-Dec |
|
Cerebral physiology of cardiac surgical patients treated with the perfluorocarbon emulsion, AF0144. | 2005 Oct |
|
Relationship among cardiac index, inspiration/expiration ratio, and perfluorocarbon dose during partial liquid ventilation in an oleic acid model of acute lung injury in sheep. | 2005 Sep |
|
Oxygent as a top load to colloid and hyperoxia is more effective in resuscitation from hemorrhagic shock than colloid and hyperoxia alone. | 2005 Sep |
|
Partial liquid ventilation with low-dose perfluorochemical and high-frequency oscillation improves oxygenation and lung compliance in a rabbit model of surfactant depletion. | 2006 |
|
An advanced expiratory circuit for the recovery of perfluorocarbon liquid from non-saturated perfluorocarbon vapour during partial liquid ventilation: an experimental model. | 2006 Feb 3 |
|
Perflubron emulsion increases subcutaneous tissue oxygen tension in rats. | 2006 Jan-Feb |
Sample Use Guides
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08CX01
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
630718
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
631018
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
NCI_THESAURUS |
C390
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
WHO-ATC |
V08CX01
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
NCI_THESAURUS |
C798
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
||
|
FDA ORPHAN DRUG |
141100
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB05791
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
SUB09721MIG
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
DD-10
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200866
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
2102
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
Q1D0Q7R4D9
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
DTXSID5046560
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
1510801
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
C1422
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
207-028-4
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
PERFLUBRON
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
9873
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
100000082730
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
C003072
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
m8540
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | Merck Index | ||
|
6903
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
38803
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY | |||
|
423-55-2
Created by
admin on Sat Dec 16 18:04:29 UTC 2023 , Edited by admin on Sat Dec 16 18:04:29 UTC 2023
|
PRIMARY |
ACTIVE MOIETY